All In Biotech

Drug Trial Radar · NCT04553133

PF-07104091 as a Single Agent and in Combination Therapy

PHASE 1/2A DOSE ESCALATION, FINDING AND EXPANSION STUDY EVALUATING SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF-07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY

Last checked: Nov 19, 2026Latest source record: May 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

157

Actual

Start

Sep 16, 2020

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Sep 17, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To assess the safety and tolerability of increasing doses of PF-07104091 and to estimate the Maximum Tolerated Dose (MTD) and/or select the Recommended Phase 2 dose (RP2D) for PF-07104091 as a single agent in participants with advanced or metastatic small cell lung, breast and ovarian cancers.

Conditions

  • Small Cell Lung Cancer
  • Ovarian Cancer
  • Breast Cancer

Interventions

  • PF-07104091 monotherapy dose escalationDrug

    PF-07104091 will be administered orally

  • PF-07104091 + palbociclib + fulvestrantDrug

    PF-07104091 will be administered orally in combination with palbociclib and fulvestrant

  • PF-07104091 + palbociclib + letrozoleDrug

    PF-07104091 will be administered orally in combination with palbociclib and letrozole

  • PF-07104091 monotherapy dose expansion (ovarian)Drug

    PF-07104091 will be administered orally

  • PF-07104091 monotherapy dose expansion (SCLC)Drug

    PF-07104091 will be administered orally

  • PF-07104091 + Fulvestrant (post CDK4/6)Drug

    PF-07104091 will be administered orally in combination with fulvestrant

  • PF-0704091 + Fulvestrant (post CDK4/6)Drug

    PF-07104091 + fulvestrant (post 4/6) dose expansion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Escalation: Number of participants with Dose-limiting toxicities (DLT) during first cycleTime frame: 28 days
  2. To evaluate incidence of treatment emergent adverse events and laboratory abnormalitiesTime frame: From baseline until end of study treatment or study completion (approximately 2 years)
  3. Evaluate pulse rate that is out of normal range and changes in pulse rate as compared to baselineTime frame: From baseline until end of study treatment or study completion (approximately 2 years)
  4. Evaluate blood pressure that is out of normal range and changes in blood pressure as compared to baselineTime frame: From baseline until end of study treatment or study completion (approximately 2 years)
  5. To evaluate heart rate corrected QT interval and changes in corrected QT interval as compared to baselineTime frame: From baseline until end of study treatment or study completion (approximately 2 years)
  6. To evaluate the preliminary antitumor activity of PF-07104091 as a single agent and in combination with palbociclib and in combination with letrozole or fulvestrant or fulvestrant alone by objective response rate (ORR) in dose expansionTime frame: From baseline through disease progression or study completion (approximately 2 years)

Locations

22 sites in 4 countries. Site status is shown where the registry gives one.

  • Medical Oncology & Hematology Associates DBA Mission Cancer and Blood

    Clive, Iowa

  • Des Moines Oncology Research Association

    Des Moines, Iowa

  • Medical Oncology & Hematology Associates DBA Mission Cancer and Blood

    Des Moines, Iowa

  • Medical Oncology & Hematology Associates DBA Mission Cancer and Blood

    Des Moines, Iowa

  • Norton Hospital

    Louisville, Kentucky

  • Norton Cancer Institute, St. Matthews Campus

    Louisville, Kentucky

  • Norton Cancer Institute, Audubon

    Louisville, Kentucky

  • Norton Brownsboro Hospital

    Louisville, Kentucky

  • Norton Cancer Institute, Brownsboro Campus

    Louisville, Kentucky

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Dana-Farber Cancer Institute - Chestnut Hill

    Newton, Massachusetts

  • Memorial Sloan Kettering Monmouth

    Middletown, New Jersey

  • Memorial Sloan Kettering Cancer Center (IDS Pharmacy)

    Long Island City, New York

  • Laura & Isaac Perlmutter Cancer Center - NYU ACC

    New York, New York

  • NYU Langone Medical Center (Tisch Hospital)

    New York, New York

  • White Plains Hospital

    White Plains, New York

  • UVA Breast Care Center

    Charlottesville, Virginia

  • Centro de Investigaciones Medicas y Desarrollo LC

    Buenos Aires, Buenos Aires F.D., Argentina

  • Complex Oncology Center - Plovdiv EOOD

    Plovdiv, Bulgaria

  • Complex Oncology Center - Shumen

    Shumen, Bulgaria

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.